Welcome. I'm Dr. Vinay Prasad. I'm a hematologist, oncologist, and I'm associate professor of medicine at the University of California, San Francisco. In my professional life, I see patients, I teach trainees, and I do research in health care policy. This is plenary session.

Plenary session is a podcast at the intersection of medicine, oncology, and health policy,

and you're listening to Season 3. On this week's episode, I've got a very brief discussion of the

dose response between PPI's and the risk of acquisition of COVID-19.

It's one of those rare instances where someone on the internet says, go write a letter to the editor.

And that person is, in fact, the editor.

You won't want to miss this.

Next up, I'm going to talk about time to treatment initiation in cancer medicine.

Is it good?

Is it bad?

How do you make sense of

these studies? This is going to be a philosophical discussion of research. You won't want to miss

this. And our interview this week is Dr. Lenora Saxinger, who's an expert in infectious

disease and hospital infection control, and you won't want to miss this discussion with

overtures to COVID-19. So, stay tuned. If you like this podcast and want more content, follow me on Twitter at Viprasad MDMPH.

Check out the YouTube channel, Vinayprasad MDMPH.

Patreon backers will get access to the slides for lectures I give on plenary session.

Want to hear from us?

Email us your question at plenary session podcast at gmail.com.

First up, Darren Dolly on Twitter.

You know, this was a thread that one of my favorite statisticians

to follow Dr. Darren Dolly, who tweets at Stats Epi, put out. And this is about, I think, COVID-19

...